|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMED2 |
Gene summary for TMED2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMED2 | Gene ID | 10959 |
| Gene name | transmembrane p24 trafficking protein 2 | |
| Gene Alias | P24A | |
| Cytomap | 12q24.31 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q15363 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10959 | TMED2 | GSM4909281 | Human | Breast | IDC | 2.66e-43 | 6.86e-01 | 0.21 |
| 10959 | TMED2 | GSM4909286 | Human | Breast | IDC | 7.85e-03 | -7.73e-03 | 0.1081 |
| 10959 | TMED2 | GSM4909288 | Human | Breast | IDC | 3.87e-02 | -2.37e-01 | 0.0988 |
| 10959 | TMED2 | GSM4909290 | Human | Breast | IDC | 1.92e-05 | 3.24e-01 | 0.2096 |
| 10959 | TMED2 | GSM4909294 | Human | Breast | IDC | 1.30e-07 | -3.25e-01 | 0.2022 |
| 10959 | TMED2 | GSM4909296 | Human | Breast | IDC | 6.23e-13 | -1.29e-01 | 0.1524 |
| 10959 | TMED2 | GSM4909297 | Human | Breast | IDC | 4.31e-30 | 1.98e-01 | 0.1517 |
| 10959 | TMED2 | GSM4909301 | Human | Breast | IDC | 9.18e-05 | -1.96e-01 | 0.1577 |
| 10959 | TMED2 | GSM4909304 | Human | Breast | IDC | 1.09e-12 | 4.44e-01 | 0.1636 |
| 10959 | TMED2 | GSM4909305 | Human | Breast | IDC | 1.02e-06 | 3.15e-01 | 0.0436 |
| 10959 | TMED2 | GSM4909306 | Human | Breast | IDC | 1.29e-04 | 3.35e-01 | 0.1564 |
| 10959 | TMED2 | GSM4909308 | Human | Breast | IDC | 6.05e-25 | 5.27e-01 | 0.158 |
| 10959 | TMED2 | GSM4909309 | Human | Breast | IDC | 7.42e-06 | -2.58e-01 | 0.0483 |
| 10959 | TMED2 | GSM4909311 | Human | Breast | IDC | 4.24e-46 | -3.10e-02 | 0.1534 |
| 10959 | TMED2 | GSM4909312 | Human | Breast | IDC | 4.86e-62 | 7.91e-01 | 0.1552 |
| 10959 | TMED2 | GSM4909313 | Human | Breast | IDC | 4.26e-20 | 4.02e-01 | 0.0391 |
| 10959 | TMED2 | GSM4909319 | Human | Breast | IDC | 5.03e-62 | -4.82e-01 | 0.1563 |
| 10959 | TMED2 | GSM4909320 | Human | Breast | IDC | 1.39e-13 | -6.68e-01 | 0.1575 |
| 10959 | TMED2 | GSM4909321 | Human | Breast | IDC | 1.05e-24 | 1.72e-01 | 0.1559 |
| 10959 | TMED2 | brca3 | Human | Breast | Precancer | 4.99e-02 | 2.68e-01 | -0.0263 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000698423 | Skin | cSCC | ER-nucleus signaling pathway | 29/4864 | 46/18723 | 1.33e-07 | 3.05e-06 | 29 |
| GO:0030968110 | Skin | cSCC | endoplasmic reticulum unfolded protein response | 40/4864 | 74/18723 | 2.52e-07 | 5.28e-06 | 40 |
| GO:00069039 | Skin | cSCC | vesicle targeting | 28/4864 | 45/18723 | 3.26e-07 | 6.57e-06 | 28 |
| GO:004355514 | Skin | cSCC | regulation of translation in response to stress | 16/4864 | 20/18723 | 6.71e-07 | 1.26e-05 | 16 |
| GO:004593628 | Skin | cSCC | negative regulation of phosphate metabolic process | 160/4864 | 441/18723 | 8.89e-07 | 1.63e-05 | 160 |
| GO:005165018 | Skin | cSCC | establishment of vesicle localization | 70/4864 | 161/18723 | 1.02e-06 | 1.82e-05 | 70 |
| GO:001056328 | Skin | cSCC | negative regulation of phosphorus metabolic process | 160/4864 | 442/18723 | 1.04e-06 | 1.85e-05 | 160 |
| GO:00901147 | Skin | cSCC | COPII-coated vesicle budding | 20/4864 | 29/18723 | 1.50e-06 | 2.57e-05 | 20 |
| GO:004355814 | Skin | cSCC | regulation of translational initiation in response to stress | 12/4864 | 14/18723 | 4.93e-06 | 7.19e-05 | 12 |
| GO:01404676 | Skin | cSCC | integrated stress response signaling | 16/4864 | 22/18723 | 5.92e-06 | 8.44e-05 | 16 |
| GO:005164816 | Skin | cSCC | vesicle localization | 73/4864 | 177/18723 | 6.36e-06 | 8.92e-05 | 73 |
| GO:00070296 | Skin | cSCC | endoplasmic reticulum organization | 42/4864 | 87/18723 | 6.36e-06 | 8.92e-05 | 42 |
| GO:004232626 | Skin | cSCC | negative regulation of phosphorylation | 137/4864 | 385/18723 | 1.63e-05 | 1.99e-04 | 137 |
| GO:00482076 | Skin | cSCC | vesicle targeting, rough ER to cis-Golgi | 11/4864 | 13/18723 | 1.64e-05 | 1.99e-04 | 11 |
| GO:00482086 | Skin | cSCC | COPII vesicle coating | 11/4864 | 13/18723 | 1.64e-05 | 1.99e-04 | 11 |
| GO:00069018 | Skin | cSCC | vesicle coating | 13/4864 | 17/18723 | 1.92e-05 | 2.27e-04 | 13 |
| GO:000189223 | Skin | cSCC | embryonic placenta development | 39/4864 | 82/18723 | 2.08e-05 | 2.43e-04 | 39 |
| GO:006145825 | Skin | cSCC | reproductive system development | 149/4864 | 427/18723 | 2.30e-05 | 2.65e-04 | 149 |
| GO:004860824 | Skin | cSCC | reproductive structure development | 148/4864 | 424/18723 | 2.40e-05 | 2.74e-04 | 148 |
| GO:000193326 | Skin | cSCC | negative regulation of protein phosphorylation | 123/4864 | 342/18723 | 2.48e-05 | 2.82e-04 | 123 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMED2 | SNV | Missense_Mutation | c.461N>A | p.Arg154Gln | p.R154Q | Q15363 | protein_coding | deleterious(0.03) | benign(0.319) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD | |
| TMED2 | SNV | Missense_Mutation | c.542T>A | p.Val181Asp | p.V181D | Q15363 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-BH-A1F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TMED2 | SNV | Missense_Mutation | c.142G>C | p.Glu48Gln | p.E48Q | Q15363 | protein_coding | tolerated(0.2) | possibly_damaging(0.654) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |
| TMED2 | SNV | Missense_Mutation | novel | c.253C>G | p.His85Asp | p.H85D | Q15363 | protein_coding | tolerated(0.09) | benign(0.022) | TCGA-ZJ-A8QR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TMED2 | SNV | Missense_Mutation | c.319N>T | p.Met107Leu | p.M107L | Q15363 | protein_coding | tolerated(0.15) | benign(0.046) | TCGA-AA-3684-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| TMED2 | SNV | Missense_Mutation | c.299C>T | p.Thr100Ile | p.T100I | Q15363 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMED2 | SNV | Missense_Mutation | c.131G>A | p.Gly44Asp | p.G44D | Q15363 | protein_coding | deleterious(0.04) | possibly_damaging(0.876) | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR | |
| TMED2 | SNV | Missense_Mutation | novel | c.532C>T | p.Leu178Phe | p.L178F | Q15363 | protein_coding | tolerated(0.4) | benign(0.023) | TCGA-4E-A92E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMED2 | SNV | Missense_Mutation | novel | c.130G>T | p.Gly44Cys | p.G44C | Q15363 | protein_coding | deleterious(0.03) | probably_damaging(0.983) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMED2 | SNV | Missense_Mutation | c.272A>G | p.Lys91Arg | p.K91R | Q15363 | protein_coding | tolerated(0.29) | benign(0.022) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |